21324-87-8

Usage

Uses

Used in Pharmaceutical Industry:
2,5-Dichlorophenyl Glycidyl Ether is used as a reactant for the preparation of pyridazinone derivatives, which are known for their antihypertensive properties. These derivatives are valuable in the development of medications aimed at treating high blood pressure, making 2,5-Dichlorophenyl Glycidyl Ether an essential component in the pharmaceutical sector.
The chemical properties of 2,5-Dichlorophenyl Glycidyl Ether, such as its reactivity and stability, make it a suitable candidate for use in the synthesis of various pharmaceutical compounds. Its role in the preparation of antihypertensive agents highlights its importance in contributing to the development of life-saving medications.

Upstream product

• 583-78-8 2,5-dichlorophenol 
• 106-89-8 epichlorohydrin 

Downstream Products

• 53671-26-4 N-{2-[3-(2,5-Dichloro-phenoxy)-2-hydroxy-propylamino]-ethyl}-isobutyramide 
• 5790-31-8 3-<2.5-Dichlor-phenoxy>-1-isopropylamino-propanol-(2) 
• 39563-28-5 1-(2,5-dichlorophenoxy)-3-((1,1-dimethylethyl)amino)-2-propanol 

Relevant academic research and scientific papers

Exploration of the expeditious potential of Pseudomonas fluorescens lipase in the kinetic resolution of racemic intermediates and its validation through molecular docking

A profoundly time-efficient chemoenzymatic method for the synthesis of (S)-3-(4-chlorophenoxy)propan-1,2-diol and (S)-1-chloro-3-(2,5-dichlorophenoxy)propan-2-ol, two important pharmaceutical intermediates, was successfully developed using Pseudomonas fluorescens lipase (PFL). Kinetic resolution was successfully achieved using vinyl acetate as acylating agent, toluene/hexane as solvent, and reaction temperature of 30°C giving high enantioselectivity and conversion. Under optimized condition, PFL demonstrated 50.2% conversion, enantiomeric excess of 95.0%, enantioselectivity (E?=?153) in an optimum time of 1?hour and 50.3% conversion, enantiomeric excess of 95.2%, enantioselectivity (E?=?161) in an optimum time of 3?hours, for the two racemic alcohols, respectively. Docking of the R- and S-enantiomers of the intermediates demonstrated stronger H-bond interaction between the hydroxyl group of the R-enantiomer and the key binding residues of the catalytic site of the lipase, while the S-enantiomer demonstrated lesser interaction. Thus, docking study complemented the experimental outcome that PFL preferentially acylated the R form of the intermediates. The present study demonstrates a cost-effective and expeditious biocatalytic process that can be applied in the enantiopure synthesis of pharmaceutical intermediates and drugs.